Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers

Authors: Tesfaye Gelanew, Berhanu Seyoum, Andargachew Mulu, Adane Mihret, Markos Abebe, Liya Wassie, Baye Gelaw, Abebe Sorsa, Yared Merid, Yilkal Muchie, Zelalem Teklemariam, Bezalem Tesfaye, Mahlet Osman, Gutema Jebessa, Abay Atinafu, Tsegaye Hailu, Antenehe Habte, Dagaga Kenea, Anteneh Gadisa, Desalegn Admasu, Emnet Tesfaye, Timothy A. Bates, Jote Tafese Bulcha, Rea Tschopp, Dareskedar Tsehay, Kim Mullholand, Rawleigh Howe, Abebe Genetu, Fikadu G. Tafesse, Alemseged Abdissa

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

COVID-19 pandemic has a devastating impact on the economies and health care system of sub-Saharan Africa. Healthcare workers (HWs), the main actors of the health system, are at higher risk because of their occupation. Serology-based estimates of SARS-CoV-2 infection among HWs represent a measure of HWs’ exposure to the virus and could be used as a guide to the prevalence of SARS-CoV-2 in the community and valuable in combating COVID-19. This information is currently lacking in Ethiopia and other African countries. This study aimed to develop an in-house antibody testing assay, assess the prevalence of SARS-CoV-2 antibodies among Ethiopian high-risk frontline HWs.

Methods

We developed and validated an in-house Enzyme-Linked Immunosorbent Assay (ELISA) for specific detection of anti-SARS-CoV-2 receptor binding domain immunoglobin G (IgG) antibodies. We then used this assay to assess the seroprevalence among HWs in five public hospitals located in different geographic regions of Ethiopia. From consenting HWs, blood samples were collected between December 2020 and February 2021, the period between the two peaks of COVID-19 in Ethiopia. Socio-demographic and clinical data were collected using questionnaire-based interviews. Descriptive statistics and bivariate and multivariate logistic regression were used to determine the overall and post-stratified seroprevalence and the association between seropositivity and potential risk factors.

Results

Our successfully developed in-house assay sensitivity was 100% in serum samples collected 2- weeks after the first onset of symptoms whereas its specificity in pre-COVID-19 pandemic sera was 97.7%. Using this assay, we analyzed a total of 1997 sera collected from HWs. Of 1997 HWs who provided a blood sample, and demographic and clinical data, 51.7% were females, 74.0% had no symptoms compatible with COVID-19, and 29.0% had a history of contact with suspected or confirmed patients with SARS-CoV-2 infection. The overall seroprevalence was 39.6%. The lowest (24.5%) and the highest (48.0%) seroprevalence rates were found in Hiwot Fana Specialized Hospital in Harar and ALERT Hospital in Addis Ababa, respectively. Of the 821 seropositive HWs, 224(27.3%) of them had a history of symptoms consistent with COVID-19 while 436 (> 53%) of them had no contact with COVID-19 cases as well as no history of COVID-19 like symptoms. A history of close contact with suspected/confirmed COVID-19 cases is associated with seropositivity (Adjusted Odds Ratio (AOR) = 1.4, 95% CI 1.1–1.8; p = 0.015).

Conclusion

High SARS-CoV-2 seroprevalence levels were observed in the five Ethiopian hospitals. These findings highlight the significant burden of asymptomatic infection in Ethiopia and may reflect the scale of transmission in the general population.
Appendix
Available only for authorised users
Literature
2.
go back to reference Gaye B, Khoury S, Cene CW, Kingue S, N’Guetta R, Lassale C, et al. Socio-demographic and epidemiological consideration of Africa’s COVID-19 response: what is the possible pandemic course? Nat Med. 2020;26:996–9.CrossRef Gaye B, Khoury S, Cene CW, Kingue S, N’Guetta R, Lassale C, et al. Socio-demographic and epidemiological consideration of Africa’s COVID-19 response: what is the possible pandemic course? Nat Med. 2020;26:996–9.CrossRef
3.
go back to reference Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577–83.CrossRef Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577–83.CrossRef
4.
go back to reference Yitbarek K, Abraham G, Girma T, Tilahun T, Woldie M. The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic. Vaccine. 2020;38:6374–80.CrossRef Yitbarek K, Abraham G, Girma T, Tilahun T, Woldie M. The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic. Vaccine. 2020;38:6374–80.CrossRef
5.
go back to reference Kalungi A, Kinyanda E, Akena DH, Kaleebu P, Bisangwa IM. Less Severe Cases of COVID-19 in Sub-Saharan Africa: could co-infection or a recent history of Plasmodium falciparum infection be protective? Front Immunol. 2021;12:565625.CrossRef Kalungi A, Kinyanda E, Akena DH, Kaleebu P, Bisangwa IM. Less Severe Cases of COVID-19 in Sub-Saharan Africa: could co-infection or a recent history of Plasmodium falciparum infection be protective? Front Immunol. 2021;12:565625.CrossRef
6.
go back to reference Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669–77.CrossRef Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669–77.CrossRef
7.
go back to reference Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500.CrossRef Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500.CrossRef
8.
go back to reference Treibel TA, Manisty C, Burton M, McKnight Á, Lambourne J, Augusto JB, et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet Lond Engl. 2020;395:1608–10.CrossRef Treibel TA, Manisty C, Burton M, McKnight Á, Lambourne J, Augusto JB, et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet Lond Engl. 2020;395:1608–10.CrossRef
10.
go back to reference Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics. 2020;10:319.CrossRef Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics. 2020;10:319.CrossRef
12.
go back to reference Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5.
13.
go back to reference Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep. 2021;34:108737.CrossRef Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep. 2021;34:108737.CrossRef
15.
go back to reference Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, et al. Seroepidemiologic study designs for determining SARS-COV-2 transmission and immunity. Emerg Infect Dis. 2020;26:1978–86.CrossRef Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, et al. Seroepidemiologic study designs for determining SARS-COV-2 transmission and immunity. Emerg Infect Dis. 2020;26:1978–86.CrossRef
16.
go back to reference Alemu BN, Addissie A, Mamo G, Deyessa N, Abebe T, Abagero A, et al. Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia. BioRxiv. 2020;41:1821. Alemu BN, Addissie A, Mamo G, Deyessa N, Abebe T, Abagero A, et al. Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia. BioRxiv. 2020;41:1821.
17.
go back to reference Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of SARS-CoV-2 in urban and rural Ethiopia: randomized household serosurveys reveal level of spread during the first wave of the pandemic. EClinicalMedicine. 2021;35:100880.CrossRef Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of SARS-CoV-2 in urban and rural Ethiopia: randomized household serosurveys reveal level of spread during the first wave of the pandemic. EClinicalMedicine. 2021;35:100880.CrossRef
18.
go back to reference Buss LF, Prete CA, Abrahim CM, Mendrone A, Salomon T, de Almeida-Neto C, et al. COVID-19 herd immunity in the Brazilian Amazon. medRxiv. 2020;4:856. Buss LF, Prete CA, Abrahim CM, Mendrone A, Salomon T, de Almeida-Neto C, et al. COVID-19 herd immunity in the Brazilian Amazon. medRxiv. 2020;4:856.
20.
go back to reference Mukwege D, Byabene AK, Akonkwa EM, Dahma H, Dauby N, Buhendwa J-PC, et al. High SARS-CoV-2 seroprevalence in healthcare Workers in Bukavu, Eastern Democratic Republic of Congo. Am J Trop Med Hyg. 2021;104:1526–30.CrossRef Mukwege D, Byabene AK, Akonkwa EM, Dahma H, Dauby N, Buhendwa J-PC, et al. High SARS-CoV-2 seroprevalence in healthcare Workers in Bukavu, Eastern Democratic Republic of Congo. Am J Trop Med Hyg. 2021;104:1526–30.CrossRef
22.
go back to reference Usuf E, Roca A. Seroprevalence surveys in sub-Saharan Africa: what do they tell us? Lancet Glob Health. 2021;9:e724–5.CrossRef Usuf E, Roca A. Seroprevalence surveys in sub-Saharan Africa: what do they tell us? Lancet Glob Health. 2021;9:e724–5.CrossRef
25.
go back to reference Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120–34.CrossRef Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120–34.CrossRef
Metadata
Title
High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
Authors
Tesfaye Gelanew
Berhanu Seyoum
Andargachew Mulu
Adane Mihret
Markos Abebe
Liya Wassie
Baye Gelaw
Abebe Sorsa
Yared Merid
Yilkal Muchie
Zelalem Teklemariam
Bezalem Tesfaye
Mahlet Osman
Gutema Jebessa
Abay Atinafu
Tsegaye Hailu
Antenehe Habte
Dagaga Kenea
Anteneh Gadisa
Desalegn Admasu
Emnet Tesfaye
Timothy A. Bates
Jote Tafese Bulcha
Rea Tschopp
Dareskedar Tsehay
Kim Mullholand
Rawleigh Howe
Abebe Genetu
Fikadu G. Tafesse
Alemseged Abdissa
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07247-z

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.